MRNA earnings setup

MRNA earnings are on Thursday 8/3 pre-market. July 26 (Reuters) - Moderna (MRNA.O) and its partner Merck (MRK.N) said on Wednesday that they had begun enrolling patients in a late-stage study testing their personalized mRNA-based skin cancer vaccine in combination with the immunotherapy Keytruda. Data from a mid-stage study in 157 patients had shown that the vaccine combination cut the risk of recurrence or death by 44% in patients with melanoma, the most deadly form of skin cancer, when compared with Keytruda alone.

I'm posting this as a long for MRNA because of the technical entry setup heading into earnings on Thursday. MRNA future earnings guidance should be much better than the bad earnings results for Q2 2023. Technically speaking, 115 is a very good place to start a MRNA dca share or far dated expiry calls long position. 145 is MRNA anchored VWAP for 2023, so that is my upside target area for 2023.

Q2 June 2023 Consensus:
EPS: -3.84
Revenue: 319.64 M

MRNA options data:

8/18/23 expiry
Put Volume Total 118
Call Volume Total 306
Put/Call Volume Ratio 0.39
Put Open Interest Total 13,153
Call Open Interest Total 16,143
Put/Call Open Interest Ratio 0.81

1/19/2024 LEAPS
Put Volume Total 54
Call Volume Total 109
Put/Call Volume Ratio 0.50
Put Open Interest Total 56,492
Call Open Interest Total 64,044
Put/Call Open Interest Ratio 0.88